Bill Nygren Comments on Forest Laboratories

Author's Avatar
Oct 08, 2013
In the past fiscal year, we purchased Forest Laboratories, Kennametal, and Oracle, which were all discussed in prior letters. Forest (FRX)’s many new drug launches remain on track with our original estimates and we look forward to this value being demonstrated in the income statement as sales ramp relative to expenses over the next several years.

From Bill Nygren's Oakmark Select Fund third quarter 2013 commentary.